The effect of laparoscopic sleeve gastrectomy on morbid obesity and obesity-related comorbidities: A cohort study
Süleyman Çetinkünar1, Hasan Erdem1, Recep Aktimur2, Mehmet Aziret3, Sabri Özdaş4, Banu Yürekli5, Fahri Yetişir6
1Clinic of General Surgery, Adana Numune Training and Research Hospital, Adana, Turkey
2Clinic of General Surgery, Samsun Training and Research Hospital, Samsun, Turkey
3Clinic of General Surgery, Kars State Hospital, Kars, Turkey
4Clinic of General Surgery, Adıyaman Training and Research Hospital, Adıyaman, Turkey
5Department of Endocrinology, Ege University Faculty of Medicine, İzmir, Turkey
6Clinic of General Surgery, Atatürk Training and Research Hospital, Ankara, Turkey
Objective: Bariatric surgery in multimodal management modalities is a more effective method to treat morbid obesity and obesity-related comorbidities compared with nonsurgical treatments. Laparoscopic sleeve gastrectomy (LSG) was initially performed as the first stage of biliopancreatic diversion with duodenal switch in the super-obese population. In the past few years, however, LSG has been performed as a definitive procedure because of its promising early and midterm results. The aim of this study is to evaluate the efficacy of our initial LSG series of 73 patients on excess weight loss (EWL) and resolution of obesity-related comorbidities in short-term follow-up.
Material and Methods: From March 2013 to May 2014, 78 morbid obese patients with an average body mass index (BMI) of 46.3 kg/m2 underwent LSG. There is a 9-month follow-up period on average. Five patients were excluded from the study, because they could not be contacted. Comorbidities, preintervention BMI, glucose, HbA1c, and lipid profiles were recorded at 1, 6, and 12 months postintervention.
Results: After the surgery, the percent EWL (%EWL) was 58%. The mean serum glucose level, HbA1c level, LDL-cholesterol level, triglyceride level, insulin, and insulin resistance decreased significantly and the mean HDL-cholesterol level increased.
Conclusion: For the resolution of comorbidities, LSG may be used as an effective bariatric and metabolic surgery.
Keywords: Sleeve gastrectomy, bariatric surgery, morbid obesity
Ethics committee approval was received for this study from the ethics committee of Adana Numune Training and Research Hospital.
Written informed consent was obtained from patients diagnosed as morbidly obese and have sleeve gastrectomy who participated in this study. Peer-review: Externally peer-reviewed.
Concept - S.Ç., H.E.; Design - S.Ç., H.E., F.Y.; Supervision - S.Ç., H.E.; Funding - S.Ç., R.A.; Materials - M.A., S.Ö.; Data Collection and/or Processing - B.Y., R.A., S.Ö., M.A.; Analysis and/or Interpretation - B.Y., R.A., F.Y.; Literature Review - S.Ö., M.A.; Writer - S.Ç.; Critical Review - F.Y., B.Y.
No conflict of interest was declared by the authors.
The authors declared that this study has received no financial support.